Cutaneous Lupus Erythematosus – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of cutaneous lupus erythematosus (CLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of CLE for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan.
Clarivate Epidemiology’s CLE forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of CLE?
- Of all people diagnosed with CLE, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CLE over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following CLE subpopulations:
- Diagnosed prevalent cases of CLE.
- Diagnosed incident cases of CLE.
- Diagnosed prevalent cases of CLE by severity.
Note: Coverage may vary by country.
Table of contents
- Cutaneous Lupus Erythematosus - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Diagnosed Prevalence per 100,000 People of All Ages in 2021 and 2041
- Diagnosed Prevalence per 100,000 People of All Ages in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Cutaneous Lupus Erythematosus Over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Cutaneous Lupus Erythematosus Over the Next 20 Years
- Analysis of Diagnosed Prevalent Cases of Cutaneous Lupus Erythematosus in 2021 by Severity
- Analysis of Diagnosed Prevalent Cases of Cutaneous Lupus Erythematosus in 2021 by Severity
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Prevalence
- Diagnosed Incidence
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Cutaneous Lupus Erythematosus
- Studies Excluded From the Analysis of Cutaneous Lupus Erythematosus
- Risk/Protective Factors
- Risk / Protective Factors
- Risk / Protective Factors
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Rose Buckland, L.L.B., M.Sc., is an associate epidemiologist at Clarivate. While pursuing an M.Sc. in social epidemiology at University College London, she assisted with research into COVID-19 surveillance through the Africa Health Research Institute. She is interested in infectious disease epidemiology, particularly HIV/AIDS. Ms. Buckland holds a postgraduate Bachelor of Law degree from the University of Cape Town in South Africa.
Sunali Goonesekera, S.M., is a senior epidemiologist at Clarivate. Previously, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.